Clinical Trials

Several clinical trials evaluate Rhamnose as a probe to assess intestinal barrier function, carbohydrate absorption, and mucosal permeability across conditions including increased intestinal permeability, metabolic disturbances, ulcerative colitis, environmental enteropathy associated with childhood malnutrition, and irritable bowel syndrome. Ranging from Phase 1 interventional studies to non-applicable or unspecified designs, these trials feature recruitment statuses of recruiting, completed, withdrawn, and unknown. Funding is provided by academic universities, research foundations, international agencies, and corporate sponsors such as GlaxoSmithKline.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06392360 Recruiting
Metabolic Disturbance|Permeability; Increased
Appalachian State University|AGRANA
2024-05-13 Not Applicable
NCT05999708 Withdrawn
Colitis Ulcerative
GlaxoSmithKline
2023-10-31 Phase 1
NCT04109352 Unknown status
Glucose-Galactose Malabsorption|Enteropathy|Malnutrition Child|Intestinal Permeability|Linear Growth Failure
University of Virginia|International Atomic Energy Agency|Flinders University|International Centre for Diarrhoeal Disease Research Bangladesh|St. John''s Research Institute|The University of The West Indies|Mmust Masinde Muliro University of Science and Technology|Asociacion Benefica Prisma|Scottish Universities Environmental Research Centre|University of Michigan|Tropical Diseases Research Centre Zambia|Gastroenterology Services Ltd.
2019-09-01 --
NCT03986476 Completed
IBS
Örebro University Sweden
2019-03-26 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Rhamnose product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Rhamnose is a 6-deoxy monosaccharide that crosses the intestinal epithelial monolayer primarily via paracellular passive diffusion without undergoing significant active transport or cellular metabolism. Quantifying its systemic absorption and physiological clearance provides a direct marker of tight junction integrity, offering valuable diagnostic insight into gut mucosal barrier dysfunction in clinical conditions such as irritable bowel syndrome, ulcerative colitis, and environmental enteropathy.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.